Unveiling the pan-cancer landscape of S100A16 - A comprehensive analysis of prognostic significance, drug sensitivity, and immunomodulatory roles

Sep 21, 2026

Accumulating evidence supports S100A16 differential expression across human cancers, yet a unified pan-cancer assessment of its biological and clinical relevance remained insufficient. This study performs pan-cancer analyses using multiple databases to evaluate prognostic value, drug sensitivity links, genetic alterations, and immunomodulatory associations. Results show high S100A16 RNA expression across cancers, correlated with prognosis and treatment sensitivity, and related with tumor microenvironment immune infiltration, supporting its potential as an immunotherapy-oriented biomarker candidate.

LanguageEnglish

CategoryResearch & Report

FormatPDF

Pages13

Reading Time33 min

AccessFree to download

Introduction

Cancer burden and need for improved diagnosis and treatment

Advances in sequencing for genomics, transcriptomics, and personalized care

® Observational Study Unveiling the pan-cancer landscape of S100A16 A comprehensive analysis of prognostic significance, drug sensitivity, and immunomodulatory roles Shixuan Shang, BMeda ,* , Ling Hu, BMedb , Chengbi Wu, BMedc , Jin Wu, MMeda , Meixiang Chen, MMeda , Guoqiang Zhu, MMedd , Wang-yang Xu, PhDd , Yunzhi Zhang, MMedd , Ge Sun, PhDd , Zexiong Wei, BMede | Abstract
Accumulating evidence supports the notion that S100A16 exhibits differential expression in many human cancers, affecting cellular functions associated with tumorigenesis through various signaling pathways. While extensive research has been conducted on S100A16 in specific cancer types, a comprehensive evaluation of its role across diverse cancers remains lacking. To explore the prognostic significance, drug sensitivity, and immunomodulatory roles of S100A16, a thorough analysis was conducted at a pan-cancer level using multiple databases. Our findings revealed high expression of S100A16 RNA in various human cancers. Importantly, this elevated expression was linked to disease prognosis and drug sensitivity across a spectrum of cancers. Genetic alterations in S100A16 were characterized across multiple cancer types, and a confirmed correlation was observed in the prognosis of skin cutaneous melanoma (SKCM) . Furthermore, our study demonstrated a significant association between S100A16 expression and the infiltrating levels of diverse cell types in the tumor microenvironment (TME), suggesting its potential as a prognosis predictor for immunotherapy. Novel collections of miRNAs, such as has-miR-423-5p, has-miR-769-5p, has-miR-151a-3p, and has-miR-550a-5p, targeting S100A16 at a pan-cancer level were predicted through various databases. These findings contribute to a comprehensive understanding the role of S100A16 in prognosis prediction, chemotherapy, and immunotherapy, providing valuable insights for identifying novel targets in cancer treatment. | | --- | | Abbreviations: BLCA = bladder urothelial carcinoma, BRCA = breast invasive carcinoma, CESC = cervical squamous cell carcinoma and endocervical adenocarcinoma, CHOL = cholangiocarcinoma, DLBC = lymphoid neoplasm diffuse large B-cell lymphoma, ESCA = esophageal carcinoma, GBM = glioblastoma multiforme, HNSC = head and neck squamous cell carcinoma, KICH = kidney chromophobe, KIRC = kidney renal clear cell carcinoma, KIRP = kidney renal papillary cell carcinoma, LAML = acute myeloid leukemia, LGG = brain lower grade glioma, LIHC = liver hepatocellular carcinoma, LUAD = lung adenocarcinoma, LUSC = lung squamous cell carcinoma, MESO = mesothelioma, OV = ovarian serous cystadenocarcinoma, PAAD = pancreatic adenocarcinoma, PCPG = pheochromocytoma and paraganglioma, PRAD = prostate adenocarcinoma, SARC = sarcoma, SKCM = skin cutaneous melanoma, STAD = stomach adenocarcinoma, TGCT = testicular germ cell tumors, THCA = thyroid carcinoma. | | Keywords: pan-cancer, prognosis, S100A16 , tumor microenvironment (TME) | 1. Introduction Cancer remains the primary or secondary cause of premature mortality in most countries worldwide. Projections suggest that the incidence of all cancers combined will double by 2070 compared to 2020 if the latest incidence trends continue, due to demographic changes such as population aging and growth.[1] Consequently, there is an urgent need to enhance cancer diagnosis and treatment to improve survival rates and reduce mortality. Recent breakthroughs in sequencing technologies, including whole exome/genome sequencing and whole transcriptome sequencing, have significantly advanced our understanding of the genomics and transcriptomics of cancer. These advancements have not only deepened our insights into the complexities of the disease but have also paved the way for personalized healthcare approaches. Through these technologies, patients with specific characteristics, such as a distinct genetic profile, can now access tailored treatments. This personalized approach not only

FAQs

What is the main focus of this study on S100A16?

It evaluates the pan-cancer landscape of S100A16, including prognostic significance, drug sensitivity associations, and immunomodulatory roles.

How were the analyses conducted to assess S100A16 across cancers?

A thorough pan-cancer level analysis was performed using multiple databases.

What tumor microenvironment relationship does the study report for S100A16?

S100A16 expression is significantly associated with infiltration levels of diverse cell types in the tumor microenvironment, suggesting prognostic potential for immunotherapy.

Sep 21, 2026

Uploaded by River Wang